In collaboration with Instituto de Efectividad Clínica y Sanitaria (IECS) and Tulane University, SPEAC’s Special Populations team has launched a Living Systematic Review focused on the safety, effectiveness, and immunogenicity of mpox vaccines.
Access the Mpox Living Systematic Review here.
What is a Living Systematic Review (LSR)?
Living Systematic Reviews (LSRs) are comprehensive literature reviews that are continually updated, incorporating relevant new evidence as it becomes available when published in databases and clinical trial registries, which is used to conduct meta-analyses for various safety, immunogenicity and efficacy endpoints.
A robust methodological framework, including PRISMA guidelines for reporting, ensures high-quality evidence synthesis. Including a diverse range of populations, such as children, pregnant persons, and adults, allows for a comprehensive evaluation of vaccine safety and efficacy among key at-risk groups.
Interactive Insights
The LRS findings are publicly accessible online – Explore the latest results and updates at safeinpregnancy.org.
The LSR team has developed a dashboard with a description of the methods and key outputs to evaluate the safety, immunogenicity and efficacy/effectiveness of specific vaccines or platforms on selected populations. A pairwise and proportional meta-analyses web-based tool will be available soon.
Updates
Primary evidence on safety, effectiveness, and immunogenicity of identified mpox vaccines is updated every two weeks.
The mpox vaccine development pipeline is updated every 6 months.
The Lassa Fever LSR is a collaboration between:
- The Special Populations work group team of Safety Platform for Emergency vACcines (SPEAC)
- Instituto de Efectividad Clínica y Sanitaria (IECS) in Buenos Aires, Argentina
- Tulane University, in New Orleans, USA.
